- Briciclib
-
- $52.00
-
2026-07-27
- CAS:865783-99-9
- Purity: 99.11%
- Supply Ability: 10g
|
| | Phenol, 2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]-, 1-(dihydrogen phosphate) Basic information |
| Product Name: | Phenol, 2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]-, 1-(dihydrogen phosphate) | | Synonyms: | Phenol, 2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]-, 1-(dihydrogen phosphate);Briciclib,ON-014185;ON-014185;(E)-5-[[(2,4,6-Trimethoxystyryl)sulfonyl]methyl]-2-methoxyphenyl dihydrogen phosphate;2-Methoxy-5-({[(E)-2-(2,4,6-trimethoxyphenyl)vinyl]sulfonyl}methy l)phenyl dihydrogen phosphate;Briciclib(ON 013105,ON 014185);Briciclib, >98%;ON013105;ON014185;ON-013105;ON-014185 | | CAS: | 865783-99-9 | | MF: | C19H23O10PS | | MW: | 474.42 | | EINECS: | | | Product Categories: | API | | Mol File: | 865783-99-9.mol | ![Phenol, 2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]-, 1-(dihydrogen phosphate) Structure](CAS/20150408/GIF/865783-99-9.gif) |
| | Phenol, 2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]-, 1-(dihydrogen phosphate) Chemical Properties |
| storage temp. | Sealed in dry,Room Temperature | | solubility | DMF: 30 mg/ml; DMSO: 30 mg/ml | | form | A crystalline solid | | color | White to off-white | | InChI | InChI=1S/C19H23O10PS/c1-25-14-10-17(27-3)15(18(11-14)28-4)7-8-31(23,24)12-13-5-6-16(26-2)19(9-13)29-30(20,21)22/h5-11H,12H2,1-4H3,(H2,20,21,22)/b8-7+ | | InChIKey | LXENKEWVEVKKGV-BQYQJAHWSA-N | | SMILES | C1(OP(O)(O)=O)=CC(CS(/C=C/C2=C(OC)C=C(OC)C=C2OC)(=O)=O)=CC=C1OC |
| | Phenol, 2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]-, 1-(dihydrogen phosphate) Usage And Synthesis |
| Description | Briciclib is a water soluble derivative of ON 013100, a small molecule that binds to and inhibits eukaryotic translation initiation factor 4E (eIF4E). Briciclib inhibits proliferation of JEKO-1 and Mino mantle cell leukemia (MCL), MCF-7 and MDA-MB-231 breast, AGS gastric, and OE19, OE33, and LFO-1 esophageal cancer cell lines with GI50 values ranging from 9.8 to 12.2 nM. It reduces expression of cyclin D1 and c-Myc, markers of eIF4E activity, in breast and MCL cancer cell lines in a dose-dependent manner. Briciclib also induces expression of the pro-apoptotic proteins p53 and cleaved caspase-3. | | Uses | Briciclib is a useful organic intermediate employed in the synthesis of [[(phenylmethyl)sulfonyl]ethenyl]benzene derivatives with anticancer activity. | | IC 50 | eIF4 | | References | [1] NEEL JASANI. Abstract 1649: Potent anticancer activity of an orally bioavailable small molecule, ON 013100, and its water soluble derivative, briciclib, a clinical-stage eIF4E-targeted agent[J]. Cancer research, 2015, 75 1: 1649-1649. DOI: 10.1158/1538-7445.am2015-1649 |
| | Phenol, 2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]-, 1-(dihydrogen phosphate) Preparation Products And Raw materials |
|